Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading Down 6.4%

Calliditas Therapeutics AB (publ) (NASDAQ:CALT)’s share price dropped 6.4% during mid-day trading on Monday . The company traded as low as $17.50 and last traded at $17.50. Approximately 2,478 shares traded hands during mid-day trading, a decline of 69% from the average daily volume of 7,994 shares. The stock had previously closed at $18.70.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, February 22nd.

Calliditas Therapeutics AB (publ) Price Performance

The company has a debt-to-equity ratio of 2.89, a quick ratio of 3.08 and a current ratio of 3.13. The firm’s 50-day simple moving average is $20.96 and its 200 day simple moving average is $20.63.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last announced its quarterly earnings data on Wednesday, February 21st. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.02. The company had revenue of $42.45 million for the quarter, compared to the consensus estimate of $36.24 million. Calliditas Therapeutics AB (publ) had a negative net margin of 38.72% and a negative return on equity of 104.47%. During the same period in the prior year, the firm posted ($0.01) EPS. On average, sell-side analysts anticipate that Calliditas Therapeutics AB will post 0.29 earnings per share for the current fiscal year.

Institutional Trading of Calliditas Therapeutics AB (publ)

A hedge fund recently bought a new stake in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. bought a new position in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 980 shares of the company’s stock, valued at approximately $25,000. Institutional investors and hedge funds own 2.83% of the company’s stock.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.